PTEN is a PIP3 phosphatase that antagonizes oncogenic PI3-kinase signalling. Due to its critical role in suppressing the potent signalling pathway, it is one of the most mutated tumour suppressors, especially in brain tumours. It is generally thought that PTEN deficiencies predominantly result from either loss of expression or enzymatic activity. By analysing PTEN in malignant glioblastoma primary cells derived from 16 of our patients, we report mutations that block localization of PTEN at the plasma membrane and nucleus without affecting lipid phosphatase activity. Cellular and biochemical analyses as well as structural modelling revealed that two mutations disrupt intramolecular interaction of PTEN and open its conformation, enhancing polyubiquitination of PTEN and decreasing protein stability. Moreover, promoting mono-ubiquitination increases protein stability and nuclear localization of mutant PTEN. Thus, our findings provide a molecular mechanism for cancer-associated PTEN defects and may lead to a brain cancer treatment that targets PTEN mono-ubiquitination.
INTRODUCTION
The phosphatase and tensin homologue deleted from chromosome 10 (PTEN) is one of the most important tumour suppressor genes, and it is highly mutated in many types of cancers including brain, breast, kidney, lung and uterine cancers. [1] [2] [3] Many patients with brain tumours carry mutations in the PTEN genes. 1, 4 Among these, glioblastoma (GBM), the most aggressive form that is associated by a short median prognosis (3 months without treatment), has a very high frequency of mutation (~35%) in the PTEN gene. 5, 6 Importantly, PTEN deficiency in GBM has been associated with poor survival. 7, 8 Treatments are currently limited: Despite extensive surgical resection, tumour recurrence is a common event and leads to a short median life expectancy (14.6 months) even with multimodal therapy that includes surgery, chemotherapy and radiotherapy. [9] [10] [11] Therefore, it is critical to elucidate mechanisms by which defects in PTEN function contribute to tumorigenesis in GBM, which can potentially serve as targets for treatment.
The PTEN protein is a lipid phosphatase that converts the tumorigenic lipid signal, phosphatidylinositol 3,4,5-trisphosphate (PIP3), to phosphatidylinositol 4,5-bisphosphate (PIP2) at the plasma membrane in cells. The majority of PTEN is located in the cytosol, and only a fraction is recruited to the plasma membrane to precisely control PIP3 levels in a highly regulated manner. We have previously shown that this recruitment process is mediated by the membrane-binding regulatory interface and is regulated by phosphorylation of PTEN. [12] [13] [14] [15] The membrane-binding regulatory interface consists of three regions of PTEN and is located on the protein's surface. The phosphorylated C-terminal region of PTEN tightly binds to the interface and masks its access to the membrane. Upon dephosphorylation, the C-terminal tail dissociates from the membrane-binding regulatory interface and opens the conformation of PTEN, allowing it to interact with the membrane, thereby converting PIP3 to PIP2. In addition to this recruitment, opening the PTEN conformation stimulates its translocation to the nucleus, where PTEN functions in DNA repair and genome stability are likely independent of its lipid phosphatase activity. 16 Consistent with the function of the C-terminal region as a determinant of stability and nuclear translocation of PTEN, deletion of this region increases interaction of PTEN with E3 ligases NEDD4 that leads both mono-and polyubiquitylation on PTEN at the same residues K13 and K289. However, whether mono-and polyubiquitylation on PTEN compete and how these modifications are regulated remain unclear.
We further found that this membrane recruitment mechanism is defective in several cancer-associated mutations. 14 When we examined the PTEN mutations that did not affect its enzymatic activity, they specifically blocked the recruitment of PTEN to the plasma membrane. Forced tethering of these PTEN mutants to the plasma membrane using an artificial membrane anchor restored their ability to oppose tumorigenic PIP3 signalling even in the presence of cancer-associated mutations. Thus, our findings have shown the importance of regulated PTEN-membrane interactions in the tumour suppressor function of PTEN in cancers. These findings suggest that cancer-related defects in PTEN go beyond its loss of expression and inactivation of its enzymatic activity; however, the landscape of PTEN defects in human cancers remains unknown.
To investigate the spectrum of cancer-related PTEN defects, we established 17 primary cells derived from 16 GBM patients and analysed their PTEN mutations, expressions, activities and membrane localizations. We revealed an unforeseen high occurrence of amino acid substitutions that blocked localization of PTEN at the plasma membrane and nucleus, but not its enzymatic activity. These mutations were found to alter the architecture of the membrane-binding regulatory interface, leaving the protein conformation open while inactivating mechanisms that target the membrane and nucleus. This abnormally opened PTEN is subject to polyubiquitination, and therefore increased degradation. Toward rescuing these cancerlinked proteins, we show that increasing mono-ubiquitination can stabilize them and redistribute them to the nucleus.
RESULTS

Analysis of PTEN mutations in malignant GBM cells Using both immunoblotting with antibodies to PTEN and RT-PCR (Figures 1a-c)
, we examined the PTEN protein in cells obtained from 16 GBM patients. Primary human fetal neural stem cells from two embryos were used as controls. [17] [18] [19] [20] [21] Primary cells obtained from nine patients (GBMs 612, 626, 651, 832, 965, 549, 922, 963 and 854) showed undetectable amounts of PTEN proteins. Of these, three (GBMs 612, 626 and 832) showed no detectable signals in an RT-PCR assay, suggesting defects in chromosomes, transcription or mRNA stability. Six expressed mRNA, and of these, four showed PTEN with non-sense mutations (GBMs 965 and 549), in-frame deletion of exon 3 (GBM 922), or out-of frame deletion of exon 4 (GBM 854). Interestingly, one (GBM 963) had no mutations in PTEN cDNA, yet lost protein expression, suggesting that the translation or stability of PTEN was altered by mutations in the non-coding region of PTEN or in other genes. Of eight patient cells that showed expression of PTEN, six (GBMs 640, 153, 940, 911, 944 and 960) contained wild-type PTEN; GBM in these patients is unlikely caused by PTEN deficiency. Two cells (GBMs 847 and 922) were derived from the same patient at different times (primary and recurrent tumour) and showed a truncated PTEN caused by deletion of exon 3.
We found two cells, GBMs 651 and 276, each of which contained a previously uncharacterized point mutation in the PTEN coding region. The former carried L320S while the latter carried T277A. Both mutant proteins had decreased steady state levels and were located at the junction where the phosphatase and C2 domains are connected in the crystal structure of PTEN ( Figure 1d ). We have previously shown that these two domains form the membrane-binding regulatory interface that binds to the plasma membrane as well as the inhibitory phosphorylated C-terminal tail, creating a master switch to determine PTEN localization. 14 We focused on the molecular mechanisms by which  L320S and T277A block PTEN function. PTEN L320S and PTEN T277A are enzymatically active Because most cancer-associated mutations in PTEN abolish its essential phosphatase activity, we first tested whether L320S and T277A affect enzymatic activity. We immunopurified GFP fused to PTEN L320S and PTEN T277A , wild-type PTEN (PTEN WT ), a catalytically inactive PTEN C124S , and PTEN with a deletion of exon 3 (PTEN delEx3 ) from HEK293T cells. Equal amounts of immunopurified proteins were used to measure their lipid phosphatase activity against a PIP3 substrate in vitro. 15, 22 While PTEN C124S -GFP and PTEN delEx3 -GFP showed significantly suppressed lipid phosphatase activities, PTEN L320S -GFP and PTEN T277A -GFP showed activities indistinguishable from PTEN WT -GFP ( Figure 1e ). PTEN L320S and PTEN T277A have reduced activity to suppress PIP3 signalling To test whether ectopic expression of PTEN can suppress PIP3 signalling in patient-derived GBM cells, we introduced PTEN WT -GFP into GBM 651 (which expressed PTEN L320S ), GBM 965 (which expressed no PTEN proteins) and GBM 276 (which expressed PTEN T277A ). Immunoblotting of whole lysates showed that PTEN WT -GFP significantly decreased phosphorylated AKT levels in all three GBM cells (Figures 1f and g). Taking advantage of this expression system, we further tested the function of PTEN mutants in the PTEN-null GBM cell GBM 965. Steady state levels of PTEN T277A -GFP, PTEN L320S -GFP and PTEN delEx3 -GFP were significantly lower than that of PTEN WT -GFP (Figures 1h and i). When we measured AKT phosphorylation, a key signalling event downstream of PIP3 signalling, PTEN WT decreased it by more than 80% in the PTEN-null GBM 965 cells. In contrast, PTEN L320S and PTEN delEx3 showed decreased activity to suppress AKT phosphorylation ( Figure 1j ). We also examined whether PTEN expression inhibits cell migration and proliferation, both of which are stimulated by PIP3. PTEN L320S -GFP, PTEN T277A -GFP and PTEN delEx3-GFP showed decreased activity to suppress cell migration, as measured by the Transwell (Figure 1k ) or 3-D nanopattern migration assays [23] [24] [25] ( Figure 1l ). Similarly, PTEN L320S -GFP, and PTEN T277A -GFP and PTEN delEx3 -GFP were unable to effectively rescue cancer cell proliferation, compared to PTEN WT -GFP ( Figure 1m ).
Consistent with data obtained in GBM cells, unlike PTEN WT -GFP, PTEN L320S -GFP expression did not effectively suppress phospho-AkT levels in HEK293T cells, nor did PTEN C124S -GFP and PTEN delEx3 -GFP (Figures 2a and b ). PTEN T277A -GFP slightly decreased phospho-AKT levels, though to a lesser extent than PTEN L320S -GFP. Expression levels of PTEN delEx3 -GFP, PTEN L320S -GFP and PTEN T277A -GFP were significantly lower than those of PTEN WT -GFP or PTEN C124S -GFP (Figures 2a and b ), suggesting that lower protein levels might contribute to the inability of these mutant proteins to effectively suppress AKT phosphorylation. To determine if lower levels of these three fused proteins result from reduced synthesis or stability, we measured their half-lives by blocking protein synthesis; this was done with cycloheximide in the human GBM cell line U87MG, the human breast basal epithelial cell line MCF10A, which lacks PTEN and HEK293T cells (Figures 2d and e and S1A). We found that PTEN delEx3 , PTEN L320S and PTEN T277A had significantly shorter half-lives than PTEN WT or PTEN A4 , which carries alanine substitutions at S380, T382, T383 and S385 that block phosphorylation of C-terminal tail, 15 PTEN L320S cannot be stabilized by removing known destabilizing modifications in PTEN To determine the mechanism that decreases the stability of PTEN L320S in greater detail, we combined L320S with mutations that are known to increase PTEN stability. We introduced K13R, which has been shown to block ubiquitination at K13, a cause of proteasomal degradation, and C124S, a mutation that stabilizes PTEN presumably through inhibiting its enzymatic activity. 12, 13, 15 Actin We found that neither of these two mutations rescued the stability of PTEN K13R,L320S -GFP or PTEN C124S,L320S -GFP (Figures 2f and g) . Similarly, live-cell imaging showed that fluorescence intensity was not greater in PTEN K13R,L320S -GFP or PTEN C124S,L320S -GFP than in PTEN L320S -GFP (Figures 2h and i). Consistent with these observations, PTEN K13R,L320S -GFP did not decrease PIP3 levels, as revealed by the PIP3 biosensor RFP-PH AKT . Interestingly, the membranebound portion of RFP-PH AKT was 3-fold greater in PTEN C124S -GF P-expressing cells than in PTEN L320S -GFP-expressing cells, suggesting a dominant negative effect of PTEN C124S on endogenous PTEN phosphatase function, consistent with previous research. 26 We noticed that PTEN C124S -GFP showed modestly more association with the plasma membrane than did PTEN WT -GFP, consistent with previous studies; 27 however, PTEN C124S,L320S -GFP was dissociated from the plasma membrane ( Figure 2h ), further supporting that L320S decreases interactions of PTEN with the plasma membrane. It has been shown that phosphorylation of PTEN at T366 or S370 destabilizes the protein. 28, 29 To determine whether blocking phosphorylation at these two sites increases the stability of PTEN L320S , we created PTEN L320S,T366A and PTEN L320S,T366A,S370A . Immunoblotting showed that PTEN L320S -GFP, PTEN L320S,T366A -GFP and PTEN L320S,T366A,S370A -GFP were as unstable as PTEN L320S -GFP (Figures 2j and k). These three constructs consistently failed to decrease AKT phosphorylation levels (Figures 2j and l).
Low cellular PTEN phosphatase activity by GBM mutants does not result solely from their lower steady state levels
When we examined intracellular localization of PTEN mutants using fluorescence microscopy, PTEN delEx3 -GFP, PTEN L320S -GFP and PTEN T277A -GFP showed uniform distributions in the cytosol, similar to that seen of PTEN WT -GFP, although the overall fluorescence intensity of the three mutants was lower than that of PTEN WT -GFP ( Figure 3a ). The PM/cytosolic fluorescence ratio of GFP fused to wild-type or mutant PTENs was not affected by amounts of their expression (data not shown). Consistent with immunoblotting using anti-phospho-AKT antibodies, quantitative live-cell imaging using a PIP3 biosensor, RFP-PH AKT , which specifically binds to PIP3 in the plasma membrane, showed that expression of PTEN WT -GFP greatly reduced PIP3 levels. This was measured by comparing the PM/cytosolic ratio of PH AKT (RFP-PH AKT intensity at the plasma membrane relative to that in the cytosol) to that of PTEN-GFP in HEK293T cells ( Figure 3b ). PTEN T277A -GFP also decreased PIP3 levels, though not as strongly as did PTEN WT -GFP (Figures 3a and b ). PTEN L320S -GFP and the enzymatically inactive PTEN delEx3 -GFP did not decrease PIP3 levels (Figures 3a and b ). To determine whether protein expression levels contribute to the effect of wild-type and mutant PTEN-GFP on PIP3 levels, we quantified total GFP intensity and plotted it against the PM/cytosolic fluorescence ratio of PH AKT for individual cells (Figure 3c ). At comparable expression levels, PTEN delEx3 -GFP, PTEN L320S -GFP and PTEN T277A -GFP had weaker suppression of PIP3 levels than PTEN WT -GFP ( Figure 3c ). Among the mutants, PTEN T277A -GFP induced the strongest decrease in PIP3 levels, consistent with the effect of phospho-AKT. Thus, in these three cases, lower expression level alone does not account for the inability to effectively reduce PIP3.
L320S and T277A mutations block PTEN membrane and nuclear localization
The recruitment of PTEN to the plasma membrane is crucial for PTEN activity. 13 To determine the impact of the T277A and L320S mutations on PTEN membrane localization, we introduced T277A into PTEN A4 , PTEN K13R,A4 and ePTEN, all of which are strongly recruited to the plasma membrane. 13 The use of the A4 mutation is critical to unambiguously determine the association of PTEN with the plasma membrane and nucleus as wild-type PTEN is predominantly cytoplasmic (Figure 4a ). 14 . The nuclear localization defects caused by T277A and L320S could further affect PTEN function in suppressing tumour formation, as nuclear PTEN has been implicated in chromosome stability, DNA repair and cell cycle progression. 16, [30] [31] [32] When we compared the localization of these PTEN mutants with different expression levels, consistent localization was observed regardless their amounts (data not shown), therefore impaired localization does not result from differences in their abundance.
We have previously shown that artificial tethering of PTEN to the plasma membrane restores function of PTEN mutants, which are defective in their association with the plasma membrane. 14 To understand whether forced membrane tethering of PTEN L320S rescues its defects in PIP3 signalling, we added a myristoylation sequence, derived from the plasma membrane protein PKBR1 33 Figure S2 ). We tested whether changing L320 to phospho-mimetic (L320D or L320E) or phospho-defective (L320A) amino acids affects the stability, localization or function of PTEN. Immunoblotting (Figure 5a ) and live-cell imaging ( Figure 5b ) showed that neither the phospho-mimetic PTEN L320D or PTEN L320E nor the phospho-defective PTEN L320A showed instabilities similar to that seen in PTEN L320S . In addition, introducing L320A into PTEN A4 to produce PTEN L320A,A4 did not affect the strong inhibition of membrane and nuclear localization (Figure 5d ). Finally, mass spectrometry showed that PTEN L320S was not phosphorylated at residue 320 (0 out of 82 L320S-containing peptides; Supplementary Figure S2 ). These data suggest that phosphorylation at residue 320 of PTEN L320S does not contribute to the defects in protein stability and localization.
We then tested whether L320S affects phosphorylation at other sites on PTEN. Two residues next to L320S, T319 and T321, have reportedly been phosphorylated by RhoA-associated kinase (ROCK) to promote PTEN membrane targeting 2, 34 (Figure 5c ). We found that introducing T319A and T321A mutations into PTEN L320S does not enhance protein stability (Figure 5d ). Consistent with this, treating cells with the ROCK inhibitor Y-27632 showed no effect on PTEN L320S level (Figure 5d ). Furthermore, T319A and T321A mutations did not enhance membrane localization of PTEN L320S,A4 -GFP (Figure 5e ). Our data suggest that phosphorylation at nearby residues T319 and T321 has no role in controlling protein stability and localization of PTEN L320S .
T277A and L320S open the conformation of PTEN and promote ubiquitination The crystal structure of PTEN has shown that F273 interacts with L320. 35 We hypothesize that the interactions with this amino acid is necessary to stabilize PTEN conformation (Figure 5f ). We found that an F273A mutation showed an inhibition similar to that of L320S, though milder, on both nuclear accumulation of PTEN A4 and membrane localization of PTEN K13R,A4 (Figures 5g and h) . Our results suggest that an L320-F273 interaction plays an important role in maintaining the PTEN conformation that is necessary for localization at the plasma membrane and nucleus. Supporting this, swapping amino acid residues at 273 and 320 restored the localization of PTEN and PTEN A4 in PTEN F273L,L320F -GFP and PTEN F273L,L320F,A4 -GFP, respectively (Figure 5i) .
To determine the effect of L320S and T277A on the protein conformation and folding of PTEN, we performed a trypsin digestion assay. 36 We immunopurified PTEN WT -GFP, PTEN A4 -GFP, PTEN T277A -GFP and PTEN L320S -GFP from HEK293T cells and incubated them with various concentrations of trypsin at 37°C. PTEN was analysed using SDS-PAGE followed by immunoblotting with anti-PTEN antibodies. Consistent with the open conformation of PTEN A4 , 15, 36 we found greater susceptibility of PTEN A4 -GFP than of PTEN WT -GFP to trypsin digestion (Figures 7a and b) . As with PTEN A4 -GFP, both PTEN T277A -GFP and PTEN L320S -GFP showed lower half-lives of full-length GFP fusions during trypsin digestion (Figures 6a  and b ). Importantly, fragmentation patterns of PTEN T277A and PTEN L320S are similar to each other, but distinct from that of PTEN A4 . Therefore, PTEN T277A and PTEN L320S have similar protein folding that are different from that of PTEN A4 .
To determine whether the altered protein conformations of PTEN T277A and PTEN L320S change the ubiquitination of PTEN, we co-expressed HA-ubiquitin with various GFP-PTEN constructs. GFP fusions were immunoprecipitated and analysed for ubiquitination by immunoblotting with anti-HA antibodies. We found that opening the protein conformation in PTEN A4 increased PTEN ubiquitination over that of PTEN WT (Figure 6c ). As with PTEN A4 , both PTEN T277A and PTEN L320S showed increased ubiquitination. Combinations of these mutations with A4 appear not to additionally elevate PTEN ubiquitination. We suggest that these elevated levels of ubiquitination likely account for protein instability in PTEN A4 , PTEN T277A and PTEN L320S . In contrast, by immunoblotting whole cell lysates with anti-phospho-PTEN antibodies, we show that T277A and L320S do not change phosphorylation at the C-terminal tail, which is necessary for interaction with the membrane-binding regulatory interface (Figure 6d ).
T277A and L320S inhibit the membrane-bound regulatory interface from interacting with the C-terminus
To further analyse the conformations of PTEN T277A and PTEN L320S , we measured the intramolecular interaction between the membrane-binding regulatory interface and the phosphorylated C-terminal tail of PTEN. 37 In this assay, we mixed HEK293T cell lysates containing the PTEN C-terminal tail tagged with FLAG with those containing GFP-PTEN WT , GFP-PTEN T277A or GFP-PTEN L320S . Anti-FLAG agarose beads were added to the mixture to pull down the C-terminal tail-FLAG. We found that GFP-PTEN WT , which has a closed conformation, did not co-precipitate with the tail, consistent with previous studies. 12, 13 Similarly, GFP-PTEN T277A and GFP-PTEN L320S did not bind to the C-terminal tail-FLAG (Figure 6e ). This could have resulted from either a closed conformation (a consequence of intramolecular interaction) or a loss in the ability of the membrane-binding regulatory interface to interact with the C-terminal tail. To distinguish between these mechanisms, we truncated the C-terminal tails from PTEN T277A and PTEN L320S . We found that the truncated proteins, PTEN(1-350) T277A and PTEN(1-350) L320S , were unable to bind to the C-terminal tail. These data suggest that PTEN T277A and PTEN L320S block interaction between the membrane-binding regulatory interface and the C-terminal tail (Figure 6e ).
Rescuing nuclear localization defects of PTEN T277A and PTEN L320S using ubiquitin tagging In addition to proteasome degradation, ubiquitination serves as a signal to drive the protein to the nucleus. We found that tagging PTEN WT -GFP with ubiquitin at the C-terminus of PTEN enhances its nuclear localization (Figure 7a ). We further tested the ability of the C-terminal ubiquitin tag to drive PTEN to the nucleus using PTEN K13R,A4 , which is almost completely excluded from the nucleus (Figures 7a and b) . Surprisingly, we found a significant amount of PTEN K13R,A4 -Ub-GFP accumulated in the nucleus. Therefore, the C-terminal ubiquitin tag has a strong ability to drive PTEN to the nucleus. We then tested whether the C-terminal ubiquitin tag can rescue the nuclear localization defect of PTEN L320S . We found that PTEN L320S,A4 -Ub-GFP significantly accumulated in the nucleus (Figures 7a and b) . To determine whether polyubiquitination is required for this rescuing activity, we tested ubiquitin K48R , which prevents the formation of polyubiquitin chains via Lys48 linkages. We found that PTEN L320S,A4 -Ub K48R -GFP showed increased nuclear localization, showing that polyubiquitination is not required. We also tested the effect of co-expression of PTEN L320S -GFP and ubiquitin or ubiquitin K48R instead of expression of PTEN-ubiquitin fusion proteins. Intriguingly, in the presence of ubiquitin K48R , PTEN L320S -GFP showed strong nuclear accumulation (Figures 7c  and d) . This effect requires the K48R mutation because co-expression of ubiquitin did not affect the cytosolic localization of PTEN L320S -GFP. Notably, no nuclear accumulation was observed when PTEN WT -GFP was co-expressed with either ubiquitin or ubiquitin K48R , supporting that the closed conformation of PTEN WT is resistant to ubiquitination. Furthermore, ubiquitin K48R , but not ubiquitin, increased the abundance of PTEN L320S -GFP, suggesting that the nuclear-targeting mono-ubiquitination decreases polyubiquitination, which drives the degradation of PTEN L320S -GFP.
To determine if a lysine residue is necessary for the nuclear localization of PTEN on ubiquitin K48R expression, we tested lysine residues, K13, K254 and K289, and a cluster of five lysines (K260, K263, K266, K267, K269) in the CBR3 loop: these have been shown to undergo ubiquitination and sumoylation. 15, 16, 38, 39 The substitution of K13 to arginine, but not other lysines, blocked the redistribution of PTEN WT -GFP, PTEN A4 -GFP and PTEN L320S -GFP to the nucleus (Figures 7e and f and Supplementary Figure S3 ).
DISCUSSION
In this study, we revealed that two GBM-associated mis-sense mutations in PTEN, PTEN L320S and PTEN T277A , induce defects in the intracellular localization and protein stability of PTEN. They generate enzymatically active PTENs that are unable to downregulate AKT signalling, leading to higher phospho-AKT levels and increased proliferation and migration in GBM than does wild-type PTEN. The mutated residues are located on opposite sides of the membrane-binding regulatory interface in the crystal structure of PTEN. 35 Importantly, these residues are located at the junction between the phosphatase and C2 domains, which together create the molecular surface critical for membrane localization and its regulation by the phosphorylated inhibitory C-terminal tail. One possible mechanism of blocking the interface is that the PTEN conformation is tightly closed as a result of intramolecular interactions between the interface and the phosphorylated inhibitory C-terminal tail. Unexpectedly, PTEN L320S and PTEN T277A are defective in this action because the membrane-binding regulatory interface is unable to associate with the C-terminal tail. At the same time, another key function of this interface (that is, interaction with the plasma membrane) is inhibited even though the inhibitory C-terminal tail is no longer masking this interface. This abnormally opened conformation increased polyubiquitination of PTEN and likely as a consequence of this, decreased the stability of PTEN. Polyubiquitination of PTEN controls its stability while its mono-ubiquitination and sumoylation have been suggested to regulate its nuclear localization. 16, 29, 30, 40 We speculate that simultaneous effects on both localization and stability are major contributors to PTEN deficiency in GBM (Figure 7g ). It should also be noted that PTEN L320S and PTEN T277A affect PIP3 signalling to various degrees. In this sense, it would be important to understand how this difference is created via structural analysis in future studies.
Our findings reveal that PTEN deficiency can be achieved by mutations at the junction between the phosphatase and C2 domains, inhibiting membrane and nuclear localization and enhancing protein degradation. To expand our findings to a larger perspective, we searched for mutations that are located at the same junction through the Catalogue of Somatic Mutations in Cancer (COSMIC) database: among 53 592 samples examined in this database, 3443 of them carry mutations in PTEN (6.4%),~40% of which are mis-sense mutations that occur throughout the entire molecule with two hotspots, R130 and R173. First, we found that PTEN T277 and PTEN L320 are mutated in cancer patients in addition to those analysed in our current study ( Supplementary Table S2 ). PTEN T277 was mutated in endometrium carcinoma (T-4A and T-4R), lymphoid neoplasm (T-4A) and glioma (T-4I). PTEN L320 was mutated in endometrium carcinoma (L-4V). Second, in the vicinity of PTEN T277 and PTEN L320 , there are additional amino acid residues in the C2 domain (amino acids 251-252, 270-278 and 325) that have been proposed to maintain the spatial configuration of the phosphatase and C2 domains based on the crystal structure. These residues are also mutated in different cancers and represent 27% of mis-sense mutations in the C2 domain (58 mutations/213 mutations in the C2 domain in COSMIC). The occurrence of these mutations at the junction indicates the importance of these residues in PTEN conformation, localization and function, and their alterations are commonly involved in the pathogenesis of a variety of cancers.
The identification of novel targets in GBM, a devastating brain cancer, is crucial to stop malignant cell proliferation and migration, and it will impact the survival in this patient population because personalized treatments are becoming more prevalent.
In-depth analysis of PTEN mutation in GBM is necessary for designing personalized targeted therapies. A translation potential of our findings could entail the in silico design of specific inhibitors of polyubiquitination to enhance protein stability and restore normal intracellular localization.
MATERIALS AND METHODS
RT-PCR and cloning
The mRNA from each GBM cells was prepared using an RNeasy kit (Qiagen, Hilden, Germany) according to manufacturer's protocol. The PTEN cDNA was synthesized from mRNA using the following primer pair: 5′-ctggg atccaaataaaaATGACAGCCATCATCAAAGAGATCG-3′ and 5′-ctcctcgagccGA CTTTTGTAATTTGTGTATGCTGATCTTC-3′ using the OneStep RT-PCR kit (Qiagen). It was then amplified using the same primer pair with Phusion DNA polymerase (Thermo Fisher Scientific, Waltham, MA, USA). GAPDH was used as a control and was amplified using the primer pair 5′-ATGG GGAAGGTGAAGGTCGGA-3′ and 5′-TTACTCCTTGGAGGCCATGTGGG-3′. The PTEN cDNA from each GBM cell was cloned into a pCR-Blunt II-TOPO vector using a Zero Blunt TOPO PCR cloning kit (Life Technologies, Waltham, MA, USA). GFP was fused to the 3′-end of PTEN using overlapping PCR. It was then cloned into the pcDNA3.1-TOPO vector using the primer pair 5′-caccATGACAGCCATCATCAAAG-3′ and 5′-TTACTTGTACAGCTCGTCCATG-3′ through directional TOPO cloning (Life Technologies).
The plasmids and PCR primers used in this study are listed in Supplementary Table S1 . PTEN variants were generated using overlapping extension PCR, 41 and they were cloned into either the mammalian expression vector pcDNA3.1 (Life Technologies), peGFP-C1 (Clontech, Mountain View, CA, USA), or the lentiviral vector pHR-SIN. All constructs were confirmed through DNA sequencing.
Cell culture and transfection
HEK293T cells were maintained in DMEM containing 10% FBS. Cells were transiently transfected with pcDNA3.1-PTEN-GFP or peGFP-C1-PTEN plasmids using Lipofectamine 3000 (Life Technologies) according to the manufacturer's protocol. Transfected cells were cultured overnight before analysis.
All protocols for GBM and human fetal cells were approved by the Johns Hopkins Hospital Institutional Review Board. All human brain tumour cells were derived from intraoperative tissue samples from patients treated surgically for newly diagnosed GBM at Johns Hopkins Hospital. Primary cultures of human fetal neural stem cells were derived after 18-20 weeks gestation, as previously published. [18] [19] [20] Detailed culture methodology, cell characterization and orthotropic tumour formation has been previously described. 23, 24, [42] [43] [44] [45] [46] Briefly, cells were cultured on laminin-coated dishes (1 μg/cm 2 ; L2020; Sigma, St Louis, MO, USA) in complete media (DMEM F/12 (Invitrogen 11330-032, Waltham, MA, USA), Neuroplex serum-free supplement (Gemini 400-160, Sacramento, CA, USA), 20 ng/mL EGF and bFGF (Pepro Tech, Rocky Hill, NJ, USA) and an antibiotic/antimycotic (A5955; Sigma)). Cells were passaged upon reaching confluency using 0.05% trypsin/EDTA (Gibco-BRL, Waltham, MA, USA). Cell viability was evaluated using the automated Cell Viability Analyzer Vi-Cell XR (Beckman Coulter, Brea, CA, USA).
PTEN-expressing GBM cells were generated by lentivirus transduction. To make PTEN-GFP lentiviruses, HEK293T cells were transfected with three plasmids: pHR-SIN-PTEN-GFP, pCMV-VSVG and pCMV-ΔR8.2 using Lipofectamine 3000. Virus-containing media were added to GBM cells for transduction. Cells were analysed at least 3 days after transduction.
Phosphatase activity
The phosphatase activity of PTEN was measured as described previously (see Materials and methods section). GFP-tagged wild-type and mutant variants of PTEN were expressed in HEK293T cells and immunopurified using GFP-Trap beads (ChromoTek, Hauppauge, NY, USA). Enzymatic activity was determined by measuring the phosphate release rate from PIP3 diC8 using a malachite green phosphatase assay kit (Echelon, Salt Lake City, UT, USA). The activity was normalized relative to amounts of purified PTEN-GFP proteins.
Immunoblotting
Proteins were separated using SDS-PAGE and then were transferred onto PVDF membranes. Antibodies used were: PTEN (138G6; Cell Signaling, Danvers, MA, USA), phospho-PTEN (S380/T382/T383; #9549; Cell Signaling), GFP, [47] [48] [49] AKT (#9272; Cell Signaling), phospho-AKT (#4060; Cell Signaling), HA (12CA5), actin (C-11; Santa Cruz Biotechnology, Dallas, TX, USA), and GAPDH (sc-32233; Santa Cruz). Immunocomplexes were visualized using fluorescent-labelled secondary antibodies and detected using a PharosFX Plus molecular imager (Bio-Rad, Hercules, CA, USA).
Live-cell imaging
HEK293T cells were seeded in LabTek 8-well chambered slides (Nalge Nunc, Rochester, NY, USA) with phenol red-free DMEM medium (#21063-029; Gibco) supplemented with 10% FBS before transfection. Cells were transiently transfected with PTEN-GFP and RFP-PH AKT plasmids using Lipofectamine 3000. After overnight incubation at 37°C, cells were observed on a Zeiss LSM780-FCS laser scanning confocal microscope with Zen software (Zeiss, Oberkochen, Germany). Images were analysed using ImageJ (NIH).
Immunoprecipitation
Whole-cell lysates of HEK293T cells co-expressing HA-Ub and various PTEN-GFP constructs were prepared from 6-cm culture dishes containing 200 μl lysis buffer with deubiquitinase inhibitor NEM (20 mM Tris (pH 7.5), 150 mM NaCl, 0.5% NP-40, 20 mM NEM, 10% glycerol, 1 mM EDTA, protease inhibitor cocktail and phosphatase inhibitor cocktail). GFP-trap beads conjugated with anti-GFP antibodies were added to the lysates and incubated for 2 h at 4°C. The beads were washed three times, and the bound proteins were analysed using SDS-PAGE, and immunoblotting was performed using antibodies against HA and PTEN.
Trypsin digestion assay HEK293T cells were transiently transfected with pcDNA3.1-PTEN WT -GFP, pcDNA3.1-PTEN A4 -GFP, pcDNA3.1-PTEN T277A -GFP and pcDNA3.1-PTEN L320S -GFP. Cell lysates were prepared with lysis buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 0.5% NP-40, 10% glycerol, 1 mM EDTA, protease inhibitor cocktail and phosphatase inhibitor cocktail) and then incubated with GFP-trap beads to pull down GFP-tagged PTEN proteins. The beads were washed three times and then suspended in assay buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA and 10 mM DTT). Trypsin digestion was performed by incubating various amounts of trypsin with the bead suspension at 37°C for 10 min. Samples were analysed by immunoblotting with an anti-PTEN antibody.
Interactions between PTEN and its C-terminal tail
Association of PTEN with its C-terminal tail (PTEN 352-403 -YFP-FLAG) was analysed as previously described. 22 Briefly, HEK293T cells were transiently transfected with plasmids carrying the PTEN C-terminal tail (PTEN 352-403 -YFP-FLAG) or PTEN mutants. After overnight incubation, cells were lysed in lysis buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 0.5% NP-40, 10% glycerol, 1 mM EDTA, protease inhibitor cocktail and phosphatase inhibitor cocktail). The lysates were then cleared by centrifugation at 13 000 rpm for 20 min at 4°C. GFP-PTEN-containing lysates were mixed with PTEN 352-403 -YFP-FLAG lysate at a 4:1 ratio, then 15 μl beads coupled to anti-FLAG antibodies (Sigma) were added. The lysate-bead mixture was incubated at 4°C for 2 h. The bound fractions were analysed using SDS-PAGE and immunoblotting with antibodies to GFP, which recognize both GFP and YFP.
Transwell cell migration assay GBM cells (2 × 10 4 ) expressing GFP or PTEN WT -GFP were resuspended in 100 μl DMEM medium containing 0.5% FBS and then were seeded in 6.5-mm inserts with 8-μm pores (Transwell Permeable Support 3422, Corning, Corning, NY, USA), which were hung over a receiver well filled with 0.5 ml DMEM/F12 containing 2.5% FBS. The same volume was seeded in a separate well to determine the total number of cells seeded per insert. After 24 h incubation, the inside of each insert was gently wiped clean using cotton swabs to remove cells that did not transmigrate. The insert was placed under a Zeiss HAL100 epifluorescence inverted microscope, and the number of GFP-positive cells that transmigrated was counted from at least four random fields. The percentage of cells that migrated was calculated by dividing the total number of migrated cells expressing GFP by the total number of cells expressing GFP that were seeded per insert.
Nanopattern cell migration assay
Migration of glioma cells was quantified using a novel directional migration assay and a multi-well nanopatterned device constructed of transparent poly(urethane acrylate). Using UV-assisted capillary lithography, parallel nano-ridges and grooves 400 nm in width, 500 nm in depth and 400 nm apart were prepared as previously described. [23] [24] [25] 50, 51 Prior to plating, nanogrooved substrata were coated with poly-D-ornithine (10 μg/ml) for 15 min and then laminin (3 μg/cm 2 ) overnight. Cell migration was quantified using time-lapse microscopy with a motorized inverted microscope (IX81; Olympus, Center Valley, PA, USA) equipped with a Cascade 512B II CCD camera and a temperature-and gas-controlling environmental chamber. Phase-contrast and epi-fluorescence cell images were automatically recorded using Slidebook 4.1 (Intelligent Imaging Innovations, Denver, CO, USA) for 10 h at 10 min intervals.
A custom-made MATLAB script was used to calculate cell speed and persistence using time-lapse microscopy data. 23, 24, [43] [44] [45] [46] Average speeds of individual cells were calculated from the total distance moved throughout the entire cell trajectory and the total time the cell was tracked. Persistence was obtained by calculating the ratio of the shortest distance between start and end points divided by the total distance moved.
Statistics P values were calculated using the Student's t-test. *Po 0.05; **Po0.01; ***P o0.005.
